Xeris Pharmaceuticals | XERS - Current Liabilities



Xeris Pharmaceuticals reported $95.17M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Adcock Ingram Holdings ZAR 2.81B 279.84M Dec/2024
Celltrion KRW 3.4T 216.25B Mar/2025
Cspc Pharmaceutical CNY 9.63B 801.28M Dec/2024
Dianthus Therapeutics USD 20.09M 1.64M Jun/2025
Divis Laboratories Ltd 14.52B 1.61B Mar/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Kangmei Pharma CNY 5.75B 64.58M Jun/2025
Knight Therapeutics CAD 118.15M 12.32M Sep/2024
Laboratorios Farma EUR 186.51M 29.86M Jun/2025
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 6.37M 3.17M Dec/2024
Neuren Pharmaceuticals AUD 45.76M 36.79M Dec/2024
Organigram Holdings CAD 107.28M 38.32M Jun/2025
Pacira USD 313.16M 1.57M Jun/2025
Perrigo USD 1.13B 52.3M Jun/2025
Pharma Mar EUR 87.78M 8.29M Jun/2025
Qiagen NV USD 1.13B 611.37M Jun/2025
Sartorius EUR 1.55B 72.7M Jun/2025
Sino Biopharmaceutical CNY 19.56B 2.39B Dec/2024
Supernus Pharmaceuticals USD 286.36M 4.59M Jun/2025
Tilray USD 278.52M 15.02M Nov/2024
Zz Pientze Pharmaceu 3.2B 878.89M Jun/2025